Literature DB >> 2527100

Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes.

L Räsänen1, H Hyöty, M Lehto, O P Kallioniemi, T Huupponen, E Tuomilehto-Wolf, E Kaprio, P Leinikki.   

Abstract

In vivo-activated interleukin 2 receptor-positive T lymphocytes (Tac cells) are demonstrable and the autologous mixed leukocyte reaction (AMLR) is impaired in several autoimmune diseases, including type 1 insulin-dependent diabetes mellitus (IDDM). We investigated AMLR in greater detail, together with possible relationships between AMLR and Tac lymphocytes in IDDM. Coculture experiments with HLA identical patient-healthy sibling pairs revealed that both responder and stimulator cells of diabetic patients function abnormally in AMLR. Suppressive Tac lymphocytes among responder T cells seemed to impair their proliferation. The removal of Tac cells by immunomagnetic beads led to a striking enhancement of proliferation, while the restoration of AMLR cultures with enriched Tac cells was accompanied by a diminished response. The reasons for the poor stimulatory capacity of patient cells are at present unknown but may be due to altered function and/or structure of HLA-DR molecules.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527100     DOI: 10.1016/0090-1229(89)90155-4

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus.

Authors:  S A Litherland; X T Xie; A D Hutson; C Wasserfall; D S Whittaker; J X She; A Hofig; M A Dennis; K Fuller; R Cook; D Schatz; L L Moldawer; M J Clare-Salzler
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 3.  Vaccine therapies for the prevention of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.